Rhizen Pharmaceuticals S.A. announces initiation of Phase 2 study of RV1001 in dogs with T- or B-cell Lymphoma La Chaux-de-Fonds, Switzerland, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. has announced the initiation of Phase 2 study of RV1001, a novel, oral selective inhibitor of PI3K...

Rhizen Pharmaceuticals Announces Out-licensing Agreement for TGR-1202, a Novel Next Generation PI3K-delta Inhibitor La Chaux-de-Fonds, Switzerland, Sept. 23, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. today announced an out-licensing agreement for TGR-1202, a novel next generation PI3K-delta inhibitor. TG...

Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany La Chaux-de-Fonds, Switzerland, Sept. 9, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals announces a scientific poster presentation on the PI3K-delta inhibitor, TGR-1202, by the Duke University...